Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.

Latest From Ramsey Baghdadi

FDA Neuroscience Director Dunn's Appearance At Tanezumab AdComm Confirms Neurology Office Is Intact

Dunn’s participation at the panel meeting ended speculation that he left the US FDA.

FDA Drug Approval Standards

Will Pharma End Up Paying For The Infrastructure Bill?

Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?

Pricing Debate Legislation

Medicare Coverage Policy Change Opens Up Commercial Market Pathway – If Biden Likes It

Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.

Medicare Private Payers

Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel

The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?

Advisory Committees Drug Review

The Greatest FDA Advisory Committees, Part III: The Power of The Patients

With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.

Advisory Committees Drug Approval Standards

The Greatest FDA Advisory Committees, Part II: The Birth Of The ‘Pazdur Moment’

With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.

Advisory Committees Leadership
See All
UsernamePublicRestriction

Register